Microsoft word - 2010-ir-0319e.doc

Investor Relations 51368 Leverkusen Germany Bayer sues Teva and Barr for false advertising and patent
infringement in connection with Teva’s generic oral contraceptive

Gianvi™’s label falsely claims that its formula and product, now in the US market, contains the same product stabilizer as YAZ® (drospirenone & ethinyl estradiol) Bayer’s oral contraceptive Suit filed in the Northern District of Illinois (Chicago) Leverkusen, June 15, 2010 – Today, Bayer Schering Pharma AG and Bayer HealthCare
Pharmaceuticals Inc. sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC,
and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false
advertising and patent infringement in connection with Teva’s generic oral contraceptive,
Gianvi™. Teva’s product is sold as a generic version of Bayer HealthCare’s leading oral
contraceptive YAZ®.
YAZ® tablets contain an estrogen (17α-ethinylestradiol) stabilized by β-cyclodextrin (or
“betadex”) as a “clathrate“ (a protective molecular cage). Using betadex as a clathrate
improves stability and prolongs shelf life of the product. Bayer believes Teva is offering
for sale its Gianvi™ product with Physician Prescribing Information that falsely claims that
Gianvi™’s ethinyl estradiol is “stabilized by betadex as a clathrate.” Based on testing of
tablets now in the US market, Bayer believes that Teva’s Gianvi™ product does not in
fact contain ethinyl estradiol stabilized by betadex as a clathrate.
Bayer intends to seek a temporary restraining order and a preliminary injunction to stop
Teva from making false claims about its Gianvi™ product and from infringing Bayer
Schering’s U.S. Patent 5,798,338, which covers offers to sell a drug with an
ethinylestradiol that is stabilized by betadex as a clathrate. Bayer also asks that Teva
take action in the US market to correct any erroneous impression persons may have
derived concerning the nature, characteristics or qualities of Gianvi™.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of healthcare,
nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of
the world’s leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global activities of the
Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions.
Bayer HealthCare’s aim is to discover, manufacture and market products that will improve
human and animal health worldwide. Find more information at
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its
research and business activities are focused on the following areas: Diagnostic Imaging,
General Medicine, Specialty Medicine and Women's Healthcare. With innovative
products, Bayer Schering Pharma aims for leading positions in specialized markets
worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to
medical progress and strives to improve the quality of life. Find more information at
Bayer AG, Investor Relations contacts:
Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer
Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation, development or performance of the company
and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on
the Bayer website at The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.


Dermatologie 3 (dv 946)

Informations P R O F E S S I O N N E L L E S Actualités dermatologiques (DV n°946 du 02/06/07) Par William BORDEAU Clinique vétérinaire, 3, avenue Foch, 94700 Maisons-Alfort – Une étude précise l’intérêt de la fexofénadine dans le traitement symptomatique des chiens atopiques La dermatite atopique constitue l'une des principales dermatites aller-Concernant les ana

CHRISTOPHER STELLPFLUG, D.D.S. CONFIDENTIAL HEALTH HISTORY Patient Name: ______________________________________Date of Birth:_________________________________ I. CIRCLE APPROPRIATE ANSWER (Leave blank if you do not understand the question) 1. Yes / No Is your general health good? If NO, explain:____________________________________________________________________ Has there been a

Copyright © 2010-2014 Internet pdf articles